EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.
about
Molecular-targeted therapy for advanced gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerGastric biomarkers: a global reviewHelicobacter pylori infection and gastric carcinoma: Not all the strains and patients are alikePersonalized medicine in gastric cancer: Where are we and where are we going?Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyAdjuvant therapy for gastric cancer: what have we learned since INT0116?Targeting receptor tyrosine kinases in gastric cancerGastric Cancer: New Drugs - New StrategiesThe molecular background of mucinous carcinoma beyond MUC2PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells.Translating genomic profiling to gastrointestinal cancer treatment.Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination.Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations.Molecular classifications of gastric cancers: Novel insights and possible future applications.Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckDetection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancerA microRNA contribution to aberrant Ras activation in gastric cancerIdentification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancerAn EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer.Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancerEGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system reviewS-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialTargeted therapy in gastroesophageal cancers: past, present and future.C-MET overexpression and amplification in gliomasAssociation between EGFR polymorphisms and the risk of lung cancer.Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.Prognostic value of CAPZA1 overexpression in gastric cancer.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
P2860
Q24187006-209B6453-4FC1-43A0-B845-ACE2C746EA93Q26471049-E5E19101-D781-4DC1-8229-70CD94371C61Q26741859-744F6AAE-7309-477A-B5C2-E6A9499A0126Q26769946-D0934D0D-697E-4583-9543-A3A8717C09B5Q26774521-9BCB9544-546D-430B-9827-7C91A0822654Q26798420-68C0C884-3D26-455A-B61E-D24CCDE1A8C1Q27008675-2D1ABBB2-190F-4B14-B91F-FF52BD3D326FQ27013050-19111D41-66DB-44E2-A06F-1BF2528B5467Q27028079-B90B68E3-DEE8-47FF-8559-25BF44179F5DQ28083904-C91F3438-4A02-4AD5-94D1-2B8BD2D34205Q30010164-90161F97-30C7-46E1-8C7F-A9DCA70883CBQ30239109-51921806-3A93-416D-A038-DF366D099D3BQ30372640-4FFD332F-6979-4015-B1FA-D3D5FEC68977Q33632000-E5493549-5DF7-4A4A-96BA-DD41742BC4B7Q33696201-E4998FD7-1112-4994-87C7-43C689360CF5Q34159125-EC386F8B-7142-4F84-9A73-9B3F093154C7Q34301120-5A134E17-9633-4B00-AABA-BADBC9393480Q34308255-E33AB86D-218C-4D36-BAE2-05C8A1A09D1FQ34478504-102FC742-2CFD-468A-BC5D-E99C3B8A7923Q34667453-6F0122C3-9482-44BF-A50B-9A5C6DBB8531Q35032328-5D7667FE-EAB8-4E8C-B605-C20F0A7296C4Q35051995-766892B6-A9D5-42EB-939D-B88313386E49Q35554809-16295150-1796-4976-A320-F2A3AE578C13Q35591083-A679719F-E4DF-4D03-A6CC-D6218A78F8FEQ35623065-AA95D85B-58A3-4906-91C5-D8890CD587EAQ35666332-09DF95CD-CB9B-466B-AF16-25F443FAE280Q35863874-AFC98BA8-D4FB-40B7-B4C8-B95B74A0DCCFQ35895961-9D27A478-43F3-41E8-B770-14FCC462B469Q36065419-90A9DFB4-EC25-4A2E-8BE9-02584C1D3558Q36069955-B2458D79-615B-4647-80A5-C63D6DA456A2Q36134904-4D0FF6AE-7004-427C-9D36-2A5EFEF439A3Q36194219-DFD8AB9A-DF15-4434-8CB1-1FF1F8A354D1Q36294579-0D61091E-97B2-4041-80A4-301CC9297D28Q36464716-237CE21D-A6B4-421D-A523-C63135831FBBQ36464945-B1E5BD57-7A07-463E-9FB1-9941A6028935Q36525778-CC0CE8AF-D9C3-4680-8207-51530248C0B2Q36547753-2779FB83-DF9F-4EFA-AD31-27196FE34BE7Q36638061-0FFB9696-CCAA-47BF-A2D0-1066290BCDCDQ36866243-FB75A477-B415-4D40-AF34-9CF9FDF66B99Q36892840-CEC96C34-0872-4A67-AA59-E8D44DF7DE61
P2860
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
EGFR in gastric carcinomas: pr ...... ion and high gene copy number.
@en
type
label
EGFR in gastric carcinomas: pr ...... ion and high gene copy number.
@en
prefLabel
EGFR in gastric carcinomas: pr ...... ion and high gene copy number.
@en
P2093
P2860
P1433
P1476
EGFR in gastric carcinomas: pr ...... ion and high gene copy number.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2559.2008.03021.X
P577
2008-04-05T00:00:00Z